Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.64 |
| ▸ | CNR2 | P34972 | 5/20 | 0.64 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2996363 | 0.99 | CNR1 (0.62) | CNR1CNR2MAOAMAOBNR3C2 | |
| SCHEMBL14396605 | 0.94 | CNR1 (0.58) | CNR1CNR2MAOAMAOBNR3C2 | |
| SCHEMBL4783707 | 0.93 | CNR1 (0.57) | CNR1CNR2MAOAMAOBNR3C2 | |
| SCHEMBL14396247 | 0.93 | CNR1 (0.57) | CNR1CNR2MAOBNR3C2EGFR | |
| SCHEMBL2991729 | 0.90 | CNR1 (0.54) | CNR1CNR2MAOAMAOBALDH1A1 | |
| Hydrochloric Acid SCHEMBL4050641 | 0.89 | CNR1 (0.53) | CNR1CNR2MAOAMAOBALDH1A1 | |
| SCHEMBL1748630 | 0.89 | CNR1 (0.65) | CNR1CNR2NR3C2PDE5APRKCZ | |
| SCHEMBL1749136 | 0.89 | CNR1 (0.65) | CNR1CNR2NR3C2EGFRPDE5A | |
| SCHEMBL1748594 | 0.89 | CNR1 (0.65) | CNR1CNR2NR3C2PDE5APRKCZ | |
| SCHEMBL12640009 | 0.89 | CNR1 (0.65) | CNR1CNR2NR3C2EGFRPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-07-22 | — | — | US | claimed |
| EP-2079701-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-22 | — | — | EP | claimed |
| EP-1944293-A1 | Alpha-Polymorph of a substituted pyrazoline, its preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-16 | — | — | EP | claimed |
| WO-2008062424-A2 | SUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES AS CANNABINOID MODULATORS | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | claimed |
| WO-2008043544-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-04-17 | — | — | WO | claimed |
| US-20220119365-A1 | CB1R RECEPTOR BLOCKERS WITH ACYCLIC BACKBONES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-04-21 | — | — | US | disclosed |
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-07-22 | — | — | US | disclosed |
| WO-2008062424-A2 | SUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES AS CANNABINOID MODULATORS | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
| EP-1911747-A1 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | disclosed |
| EP-1849776-A1 | Azepane- or Azocane-substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-31 | — | — | EP | disclosed |
| EP-1743888-A1 | Carbonyl substituted pyrazoline compounds, their preparation and use as CB1 receptor modulators | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885MAOA 1121/4885 |
| US-20220119365-A1 | CB1R RECEPTOR BLOCKERS WITH ACYCLIC BACKBONES | CNR1, CNR2, HCRTR1 | CNR1 1/4885CNR2 2/4885MAOA 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.